89 Views | 42 Downloads
Marie Pancera, Email: mpancera@fredhutch.org
N.K.H., A.T.M., L.S., and M.P. conceived the project. N.K.H., E.S., M.S., A.T.M., L.S., and M.P designed the experiments. J.F. cloned the plasmids. N.K.H. and A.B.S. expressed and purified the proteins. N.K.H. crystallized proteins, collected and processed the diffraction data, and solved the crystal structure. N.K.H. performed kinetic experiments. V.V.E. and Y.-H.W. performed neutralization assays. E.S. performed shedding experiments. N.K.H., A.T.M., L.S., and M.P. analyzed and discussed data. N.K.H. and M.P. wrote the original manuscript draft. N.K.H., A.T.M., L.S., and M.P. reviewed and edited the manuscript.
The authors declare no competing interests. A provisional patent application (U.S. Provisional Application number 63/016268) has been filed on the SARS-CoV-2-specific monoclonal antibodies isolated herein.
This work was supported by generous donations to Fred Hutch COVID-19 Research Fund. We thank Dr. McLellan for providing the SARS-CoV-2 RBD plasmid. We thank the J. B. Pendleton Charitable Trust for its generous support of Formulatrix robotic instruments. Results shown in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center (SBC), ID-19, at the Advanced Photon Source. SBC-CAT is operated by UChicago Argonne, LLC, for the U.S. Department of Energy, Office of Biological and Environmental Research under contract DE-AC02-06CH11357. The SARS-CoV-2 neutralization assay efforts were in part supported by the Emory EVPHA Synergy Fund award, Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta, COVID-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine.
© The Author(s) 2020